December 31, 2019
XBiotech announced the closing of the sale of its True Human antibody Bermekimab to Johnson & Johnson's Janssen Biotech.
November 12, 2019
The company is evaluating its IL-1a blocking antibody therapy in patients with moderate-to-severe Atopic Dermatitis (AD).
October 2, 2019
The company announced the first patient was enrolled in a clinical study in adults with systemic sclerosis.
December 30, 2018
Dova Pharmaceuticals, Sesen Bio, Adaptimmune Therapeutics, Mustang Bio and Equillium were last week's top gainers.
December 12, 2018
XBiotech (NASDAQ:XBIT) announced today that its open label, proof of concept, multicenter study using bermekimab to treat patients with moderate...
November 4, 2018
Aptose Biosciences, Trevena, Curis, Geron and Aveo Pharmaceuticals were last week's top gainers on the NASDAQ Biotechnology Index.
July 10, 2018
XBiotech (NASDAQ:XBIT) announced today that the first patient has been enrolled in its Phase 2 open label, dose escalation clinical...